Techulon signs distribution agreement with BioConcept for Glycofect

Techulon Inc., the leader in low-toxicity gene delivery has signed a distribution agreement with BioConcept of Allschwil, Switzerland. Glycofect is a polymeric nanoparticle-delivery transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used in over 20 countries by government, university and corporate laboratories for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

"BioConcept, leading manufacturer of Swiss made cell culture media (AMIMED^®), is proud to be the partner of Techulon for distribution of Glycofect," said Martin Howald, CEO/President of BioConcept. "The innovative nature of Glycofect perfectly fits BioConcept's portfolio and the combination of Glycofect with MAM-PF - our chemically defined, protein-, serum- and animal component free CHO production medium, will give our valued customers additional benefits."

"We are very pleased to have BioConcept represent Techulon. Swiss and European institutions are leaders in cell-based therapeutics research, and as research focus shifts towards primary cells we expect to see strong growth with our Glycofect reagents," said Frank Akers, President of Techulon. "We believe that BioConcept has an excellent product portfolio and customer base that will expand our market penetration throughout Europe."